Evergreen Youth Secrets
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
No Result
View All Result
Evergreen Youth Secrets
No Result
View All Result
Home Health Care

Ozempic reduces knee osteoarthritis pain by almost half: Study

by
October 31, 2024
in Health Care
0
Ozempic reduces knee osteoarthritis pain by almost half: Study

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain among patients with knee osteoarthritis and obesity.

The study funded by Novo Nordisk, the manufacturer of Ozempic and Wegovy, involved 407 participants taking either the active ingredient semaglutide or a placebo for 68 weeks. Roughly 82 percent of participants were women.

To measure pain, researchers used the Western Ontario and McMaster Universities Arthritis Index (WOMAC). The WOMAC involves participants scoring pain, difficulty and physical function when doing everyday activities like walking up and down stairs or sitting.

At the start of the trial, the average WOMAC pain score among participants was 70.9. By the 68th week, those taking semaglutide reported an average WOMAC pain score of 29.2, while those taking a placebo reported an average pain score of 43.4.

The semaglutide participants on average had a body weight reduction of 13.7 percent, while those taking a placebo had a 3.2 percent reduction on average.

“Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo,” the study’s conclusion stated.

As the Johns Hopkins Arthritis Center notes, overweight women have almost four times the risk of developing knee osteoarthritis when compared to non-obese women. For obese men, the risk is five times higher than their non-obese counterparts.

GLP-1 agonists like semaglutide have been explored for uses beyond obesity and diabetes. Semaglutide has been studied for potential benefits for treating addiction, kidney failure, liver disease and early Alzheimer’s disease.

Previous Post

Lawsuit challenges Louisiana law classifying mifepristone, misoprostol as controlled substances

Next Post

Trump: RFK Jr. will work on ‘health and women’s health’

Next Post
Trump: RFK Jr. will work on ‘health and women’s health’

Trump: RFK Jr. will work on 'health and women's health'

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

    Popular News

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    June 27, 2025
    FDA expanding COVID vaccine warnings over rare heart side effect

    FDA expanding COVID vaccine warnings over rare heart side effect

    June 27, 2025
    Supreme Court upholds HHS authority over ObamaCare preventative care task force

    Supreme Court upholds HHS authority over ObamaCare preventative care task force

    June 27, 2025

    Trending

    FDA milk quality testing program suspended after job cuts

    FDA milk quality testing program suspended after job cuts

    April 23, 2025
    FDA approves weight-loss drug to treat sleep apnea

    FDA approves weight-loss drug to treat sleep apnea

    December 21, 2024
    Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy

    Novo Nordisk slashes Wegovy prices through direct-to-consumer pharmacy

    March 5, 2025
    Public health experts, scientists warn senators on confirming RFK Jr

    Public health experts, scientists warn senators on confirming RFK Jr

    January 13, 2025

    Recent News

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    June 27, 2025
    FDA expanding COVID vaccine warnings over rare heart side effect

    FDA expanding COVID vaccine warnings over rare heart side effect

    June 27, 2025

    Popular News

    • New Hampshire lawmakers give final approval to gender-affirming care ban 
    • FDA expanding COVID vaccine warnings over rare heart side effect

    About Evergreen Youth Secrets

    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.

    No Result
    View All Result
    • Health News
    • Health Care
    • Staying Healthy
    • Beauty Advices

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.